From the Research
Adverse Effects of Evenity (Romosozumab)
- The studies 1, 2, 3 report that romosozumab has a generally manageable tolerability profile, with common adverse effects including arthralgia, headache, and injection site reactions.
- However, none of the studies 1, 2, 4, 3, 5 specifically mention dyspnea as an adverse effect of romosozumab.
- Major adverse cardiac events were observed in one clinical trial 1, and romosozumab carries a black box warning that it should not be initiated in patients with myocardial infarction or stroke in the preceding year 3.
- The risk of cardiovascular disease with romosozumab is unclear, with conflicting information in the studies 3.
Safety and Efficacy of Evenity (Romosozumab)
- Romosozumab has been shown to significantly reduce vertebral and clinical fracture risk in postmenopausal women with osteoporosis 2, 3.
- The drug has a dual effect, increasing bone formation and reducing bone resorption, making it a valuable treatment option for patients with high fracture risk 4, 3.
- Romosozumab is recommended for osteoporosis treatment in patients at very high risk for fracture with low cardiovascular risk 3.